J9325 Insurance Policy Changes

HCPCS J9325 is officially defined as "Injection, talimogene laherparepvec, per 1 million plaque forming units." HCPCS J9325 is referenced in 2 tracked payer policy changes from Highmark and Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9325 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.